Literature DB >> 17921108

Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer.

M Moreno1, J Aristu, L I Ramos, L Arbea, J M López-Picazo, M Cambeiro, R Martínez-Monge.   

Abstract

BACKGROUND AND
PURPOSE: Radiation pneumonitis (RP) is a restricting complication of non-small-cell lung cancer irradiation. Three-dimensional conformal radiotherapy (3D-CRT) represents an advance because exposure of normal tissues is minimised. This study tries to identify prognostic factors associated with severe RP.
MATERIALS AND METHODS: Eighty patients with stage IIIA (20%) and IIIB (80%) NSCLC treated with cisplatin- based induction chemotherapy followed by concurrent chemotherapy and hyperfractionated 3D-CRT (median dose: 72.4 Gy, range: 54.1-85.9) were retrospectively evaluated. Acute and late RP were scored using RTOG glossary. Potential predictive factors evaluated included clinical, therapeutic and dosimetric factors. The lungs were defined as a whole organ. Univariate and multivariate analyses were performed.
RESULTS: Early and late RP grade>or=3 were observed in two patients (2%) and 10 patients (12%), respectively. Five patients (6%) died of pulmonary toxicity, 3 of whom had pre-existing chronic obstructive pulmonary disease (COPD). Median time to occurrence of late RP was 4.5 months (range: 3-8). Multivariate analysis showed that COPD (OR=10.1, p=0.01) and NTCPkwa>30% (OR=10.5, p=0.007) were independently associated with late grade>or=3 RP. Incidence of RP>or=3 grade for patients with COPD and/or NTCPkwa>30% was 25% vs. 4% for patients without COPD and NTCPkwa<30% (p=0.01). Risk of severe RP was higher for patients with COPD and/or NTCPkwa>30% (OR=7.3; CI 95%=1.4-37.3, p=0.016).
CONCLUSIONS: COPD and NTCP are predictive of severe RP. Careful medical evaluation and meticulous treatment planning are of paramount importance to decrease the incidence of severe RP.

Entities:  

Mesh:

Year:  2007        PMID: 17921108     DOI: 10.1007/s12094-007-0109-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  53 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.

Authors:  S Bahri; J C Flickinger; A M Kalend; M Deutsch; C P Belani; F C Sciurba; J D Luketich; J S Greenberger
Journal:  Radiat Oncol Investig       Date:  1999

3.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

4.  Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta.

Authors:  X L Fu; H Huang; G Bentel; R Clough; R L Jirtle; F M Kong; L B Marks; M S Anscher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

5.  A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).

Authors:  H Choy; R F Devore; K R Hande; L L Porter; P Rosenblatt; F Yunus; L Schlabach; C Smith; Y Shyr; D H Johnson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-01       Impact factor: 7.038

6.  Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis.

Authors:  A Inoue; H Kunitoh; I Sekine; M Sumi; K Tokuuye; N Saijo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

7.  Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.

Authors:  M A Socinski; J A Clark; J Halle; A Steagall; B Kaluzny; J G Rosenman
Journal:  Semin Oncol       Date:  1997-08       Impact factor: 4.929

8.  Risk factors of pneumonitis following chemoradiotherapy for lung cancer.

Authors:  M Yamada; S Kudoh; K Hirata; T Nakajima; J Yoshikawa
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

9.  Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.

Authors:  Sang-wook Lee; Eun Kyung Choi; Jung Shin Lee; Sang Do Lee; Cheolwon Suh; Sang-We Kim; Woo Sung Kim; Seung Do Ahn; Byong Yong Yi; Jong Hoon Kim; Young Ju Noh; Su Ssan Kim; Younsuck Koh; Dong Soon Kim; Won-Dong Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-15       Impact factor: 7.038

Review 10.  The radiotherapeutic injury--a complex 'wound'.

Authors:  James W Denham; Martin Hauer-Jensen
Journal:  Radiother Oncol       Date:  2002-05       Impact factor: 6.280

View more
  8 in total

Review 1.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.

Authors:  David A Palma; Suresh Senan; Kayoko Tsujino; Robert B Barriger; Ramesh Rengan; Marta Moreno; Jeffrey D Bradley; Tae Hyun Kim; Sara Ramella; Lawrence B Marks; Luigi De Petris; Larry Stitt; George Rodrigues
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-09       Impact factor: 7.038

2.  Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.

Authors:  Xuexi Yang; Ting Mei; Min Yu; Youling Gong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-06-20

Review 3.  Radiation-related treatment effects across the age spectrum: differences and similarities or what the old and young can learn from each other.

Authors:  Matthew J Krasin; Louis S Constine; Debra L Friedman; Lawrence B Marks
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

Review 4.  A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis.

Authors:  Ivan R Vogelius; Søren M Bentzen
Journal:  Acta Oncol       Date:  2012-09-05       Impact factor: 4.089

5.  Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.

Authors:  Branislav Jeremić; Biljana Miličić; Slobodan Milisavljevic
Journal:  Clin Transl Oncol       Date:  2012-07-12       Impact factor: 3.405

6.  PAQR4 promotes cell proliferation and metastasis through the CDK4-pRB-E2F1 pathway in non-small-cell lung cancer.

Authors:  Bin Wu; Rongyu Liu
Journal:  Onco Targets Ther       Date:  2019-05-13       Impact factor: 4.147

7.  A Semiautomated Chart Review for Assessing the Development of Radiation Pneumonitis Using Natural Language Processing: Diagnostic Accuracy and Feasibility Study.

Authors:  Jordan McKenzie; Rasika Rajapakshe; Hua Shen; Shan Rajapakshe; Angela Lin
Journal:  JMIR Med Inform       Date:  2021-11-12

Review 8.  Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review.

Authors:  Yujie Yan; Jiamei Fu; Roman O Kowalchuk; Christopher M Wright; Ran Zhang; Xuefei Li; Yaping Xu
Journal:  Transl Lung Cancer Res       Date:  2022-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.